Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Morning versus evening injection on your chosen day Once you pick the right day, you still need to choose a time
L-Carnitine , , - , L-Carnitine , , PCOS , L-Carnitine : , L-carnitine : , , L-Carnitine PCOS : L-carnitine PCOS , : L-carnitine L-Carnitine :
Please contact us for more information or visit us online now to book an appointment
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026 1,2 For the co-primary endpoints, retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the 3 "People with obesity and knee osteoarthritis often live with pain and restricted mobility, and may eventually require total joint replacement," said TRIUMPH-4 Efficacy Estimand Results In additional secondary endpoints, retatrutide reduced known markers of cardiovascular risk, including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP), and at the highest dose lowered systolic blood pressure by 14.0 mmHg, using the efficacy estimand
